Related Experiment Video

Updated: Jul 14, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Treatment of children with HIV infection

Terry C Dixon1, Coleen K Cunningham

  • 1Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA. dixon013@mc.duke.edu

Current HIV/AIDS Reports
|June 6, 2007
PubMed

Insights

Pediatric HIV treatment advances improve child longevity and quality of life through new antiretroviral drugs and better understanding of pharmacokinetics and toxicities. This review covers emerging pediatric HIV therapies and vaccines.

Area of Science:

  • Pediatric Infectious Diseases
  • Antiretroviral Therapy Research
  • HIV/AIDS Clinical Management

Background:

  • Significant advancements in pediatric HIV infection management have enhanced long-term viral suppression.
  • Improvements in children's quality of life and longevity are linked to better HIV treatment strategies.
  • Key factors include novel antiretroviral medications, pediatric pharmacokinetics, and understanding drug toxicities.

Purpose of the Study:

  • To review emerging antiretroviral agents for pediatric HIV treatment.
  • To discuss new pharmacokinetic and toxicity data specific to pediatric patients.
  • To provide updated information on essential vaccines for children with HIV infection.

Main Methods:

  • Literature review of recent studies on pediatric HIV treatment.
  • Analysis of pharmacokinetic and toxicity data in pediatric populations.
  • Synthesis of information on novel antiretroviral drugs and pediatric vaccines.

Main Results:

  • Newer antiretroviral agents show promise for future pediatric HIV therapy.
  • Updated pharmacokinetic and toxicity profiles are crucial for pediatric drug use.
  • Vaccination guidelines are essential for improving health outcomes in children with HIV.

Conclusions:

  • Ongoing research and development are critical for advancing pediatric HIV care.
  • Personalized approaches considering pharmacokinetics and toxicities improve treatment efficacy.
  • Comprehensive management, including vaccination, enhances the well-being of children living with HIV.

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...